News
Barclays Maintains Overweight on Insmed, Raises Price Target to $40
11 Apr 24
News, Price Target, Analyst Ratings
Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target
1 Apr 24
News, Price Target, Analyst Ratings
On March 8, Insmed Received Notice Of Exercise By Astrazeneca AB Of Its Second And Final Option Under License Agreement, Dated Oct 4, 2016
11 Mar 24
Biotech, News, Contracts, General
Guggenheim Maintains Buy on Insmed, Raises Price Target to $54
27 Feb 24
News, Price Target, Analyst Ratings
UBS Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $46
27 Feb 24
News, Price Target, Initiation, Analyst Ratings
Insmed Q4 2023 Adj EPS $(1.28) Misses $(1.15) Estimate, Sales $83.70M Beat $82.76M Estimate
22 Feb 24
Earnings, Earnings Beats, Earnings Misses, News
Earnings Scheduled For February 22, 2024
22 Feb 24
Earnings
Wolfe Research Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $42
15 Feb 24
News, Price Target, Initiation, Analyst Ratings
Press releases
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5 Apr 24
Press Releases
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
27 Mar 24
Press Releases
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
22 Feb 24
Earnings, Press Releases
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
8 Feb 24
Press Releases
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 Feb 24
Press Releases